Amonoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and non-EGFR-mediated pathways

Molecular Cancer Therapeutics

Volumn 14, Issue 7, 2015, Pages 1637-1649

  Rios Doria, Jonathan ^a   Sabol, Darrin ^a   Chesebrough, Jon ^a   Stewart, Dave ^a   Xu, Linda ^a   Tammali, Ravinder ^a   Cheng, Li ^a   Du, Qun ^a   Schifferli, Kevin ^a   Rothstein, Ray ^a   Leow, Ching Ching ^a   Heidbrink Thompson, Jenny ^a   Jin, Xiaofang ^a   Gao, Changshou ^a   Friedman, Jay ^b   Wilkinson, Brandy ^b   Damschroder, Melissa ^a   Pierce, Andrew J ^a   Hollingsworth, Robert E ^a   Tice, David A ^a   Michelotti, Emil F ^a   more..

^a MEDIMMUNE   (United States)

^b Champions Oncology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MEDI 13622; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; ADAM PROTEIN; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; ENZYME SUBSTRATE; ESOPHAGEAL CANCER CELL LINE; ESOPHAGUS CANCER; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; SIGNAL TRANSDUCTION; TREATMENT INDICATION; TUMOR MODEL; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DBA MOUSE; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HCT116 CELL LINE; HT 29 CELL LINE; IMMUNOLOGY; METABOLISM; NEOPLASMS; NUDE MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE; WESTERN BLOTTING;

ADAM PROTEINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CETUXIMAB; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HCT116 CELLS; HT29 CELLS; HUMANS; MICE, INBRED DBA; MICE, NUDE; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942106186     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-1040     Document Type: Article

References (41)

1. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, WolfsonMF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-Ø from cells. Nature 1997;385:729-33.
2. MossML, Jin S-C, Milla ME, Burkhart W, Carter HL, ChenWJ, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997;385:733-6.
3. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, et al. An essential role for ectodomain shedding in mammalian development. Science 1998;282:1281-4.
4. Jackson LF, Qiu TH, Sunnarborg SW, Chang A, Zhang C, Patterson C, et al. Defective valvulogenesis in HB-EGF and TACE-nullmice is associated with aberrant BMP signaling. EMBO J 2003;22:2704-16.
5. Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, Werb Z, et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995;376:337-41.
6. Sahin U, Weskamp G, Kelly K, Zhou H-, Higashiyama S, Peschon J, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004;164:769-79.
7. Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 2007;117:337-45.
8. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S, et al. Increases of amphiregulin and transforming growth factor-a in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005;65:9176-84.
9. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 2010;45:146-69.
10. Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011;8:492-503.
11. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-41.
12. Murumkar PR, Giridhar R, Yadav MR. Novel methods and strategies in the discovery of TACE inhibitors. Expert Opin Drug Discov 2013;8:157-81.
13. Li NG, Shi ZH, Tang YP, Wei-Li, Lian-Yin, Duan JA. Discovery of selective small molecular TACE inhibitors for the treatment of rheumatoid arthritis. Curr Med Chem 2012;19:2924-56.
14. Zask A, Kaplan J, DuX, MacEwan G, Sandanayaka V, Eudy N, et al. Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors. Bioorg Med Chem Lett 2005;15:1641-5.
15. Le Gall SM, Maretzky T, Issuree PDA, Niu XD, Reiss K, Saftig P, et al. ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Sci 2010;123:3913-22.
16. Tape CJ, Willems SH, Dombernowsky SL, Stanley PL, Fogarasi M, Ouwehand W, et al. Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci U S A 2011;108:5578-83.
17. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996;14:309-14.
18. Willems SH, Tape CJ, Stanley PL, Taylor NA, Mills IG, Neal DE, et al. Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem J 2010;428:439-50.
19. Schlöndorff J, Becherer JD, Blobel CP. Intracellular maturation and localization of the tumour necrosis factor a convertase (TACE). Biochem J 2000;347:131-8.
20. Xu P, Derynck R. Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. Mol Cell 2010;37:551-66.
21. Xu P, Liu J, Sakaki-Yumoto M, Derynck R. TACE activation by MAPKmediated regulation of cell surface dimerization and TIMP3 association. Science Signaling 2012;5.
22. Chokki M, Mitsuhashi H, Kamimura T. Metalloprotease-dependent amphiregulin release mediates tumor necrosis factor-a-induced IL-8 secretion in the human airway epithelial cell line NCI-H292. Life Sci 2006;78:3051-7.
23. Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, et al. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressingwild-type and mutated epidermal growth factor receptor. Clin Cancer Res 2007;13:1540-51.
24. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010;70:2485-94.
25. Amos S, Martin PM, Polar GA, Parsons SJ, Hussaini IM. Phorbol 12-myristate 13-acetate induces epidermal growth factor receptor transactivation via protein kinase Cd/c-src pathways in glioblastoma cells. J BiolChem 2005;280:7729-38.
26. Maretzky T, Zhou W, Huang X-, Blobel CP. A transforming src mutant increases the bioavailability of EGFR ligands via stimulation of the cellsurface metalloproteinase ADAM17. Oncogene 2011;30:611-8.
27. Kabolizadeh P, Kubicek GJ, Heron DE, Ferris RL, Gibson MK. The role of cetuximab in the management of head and neck cancers. Expert Opin Biol Ther 2012;12:517-28.
28. Yarom N, Jonker DJ. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med 2011;11:95-105.
29. Lui VWY, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, et al. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A 2014;111:1114-9.
30. Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2(HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res 2010;16:1159-69.
31. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control inmetastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7.
32. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009;27:5068-74.
33. Janmaat ML, Kruyt FAE, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or akt kinase pathways. Clin Cancer Res 2003;9:2316-26.
34. Morris LGT, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, et al. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A 2011;108:19024-9.
35. Aicher B, LerchMM, Müller T, Schilling J, Ullrich A. Cellular redistribution of protein tyrosine phosphatases LAR and PTPs by inducible proteolytic processing. J Cell Biol 1997;138:681-96.
36. Simon E, Petke D, Böger C, Behrens HM, Warneke V, Ebert M, et al. The spatial distribution of LGR5+ cells correlates with gastric cancer progression. PLoS ONE 2012;7:e35486.
37. Chen X, Chen L, Zhang R, Yi Y, Ma Y, Yan K, et al. ADAM17 regulates selfrenewal and differentiation of U87 glioblastoma stem cells. Neurosci Lett 2013;537:44-9.
38. Lu J, Ye X, Fan F, Xia L, Bhattacharya R, Bellister S, et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of jagged-1. Cancer Cell 2013;23:171-85.
39. Paschen A, Sucker A, Hill B, Moll I, ZapatkaM, Xuan DN, et al. Differential clinical significance of individual NKG2D ligands in melanoma: Soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 2009;15:5208-15.
40. Liu G, Lu S, Wang X, Page ST, Higano CS, Plymate SR, et al. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinomametastasis. J Clin Invest 2013;123:4410-22.
41. Garrido G, Rabasa A, Sánchez B, López MV, Blanco R, López A, et al. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol 2011;187:4954-66.